Date: 2013-10-22
Type of information: Licensing agreement
Compound: rights to filgrastim and pegfilgrastim in approximately 100 markets
Company: Amgen (USA - CA) Roche (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On October 22, 2013, Amgen has announced that it has entered into a definitive agreement with Roche to acquire Roche\'s rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, (a joint venture between Amgen and Kirin Holdings) in Eastern Europe, Latin America, Asia, the Middle East and Africa since 1989. The franchise generated approximately $200 million in sales in these territories in 2012.
Filgrastim and pegfilgrastim are white blood cell boosting therapeutics used to reduce the risk of infection in patients receiving chemotherapy. They are marketed by Amgen in the United States and Europe under the trade names Neupogen® and Neulasta®, respectively. Amgen anticipates this deal will be accretive starting in 2014.
Amgen will begin distributing and selling product as soon as practical in countries where the Company has an existing commercial presence. In countries where Amgen does not have a presence, Roche or its distributors will continue to sell and distribute the products for an interim transition period.
Financial terms:
Latest news:
